Deciphera Pharmaceuticals to Present Updated Data from Ongoing Phase 1 Study of DCC-2618 at the 2017 European Society for Medical Clinical Oncology Annual Congress
Waltham, MA – August 31, 2017 – Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that updated data from its ongoing Phase 1 clinical study of DCC-2618, the Company’s pan-KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors (GIST) will be presented as a proffered paper at the 2017 European Society for Medical Clinical Oncology Annual Congress (ESMO) Annual Congress taking place September 8 – 12, 2017, in Madrid, Spain.
“We are very pleased that the ongoing Phase 1 trial of DCC-2618 continues to be well-tolerated and demonstrate encouraging disease control, with objective responses and prolonged stable disease, in heavily pre-treated GIST patients,” said Michael D. Taylor, Ph.D., Deciphera’s President and Chief Executive Officer.
“Next generation sequencing of plasma cell-free DNA was performed throughout the Phase 1 trial to quantify KIT, PDGFRα and other molecular alterations,” added Oliver Rosen, M.D., Deciphera’s Chief Medical Officer. “DCC-2618 produced reductions in the mutation allele frequencies for KIT across exons 9, 11, 13, 14, 17 and 18, demonstrating a broad spectrum of activity that included reductions in patients with KIT mutations known to confer resistance to imatinib.”
Details of the oral presentation are as follows:
Poster Title: Encouraging activity of novel pan-KIT and PDGFRα inhibitor DCC-2618 in patients with Gastrointestinal Stromal Tumor (GIST).
Author: Filip Janku, M.D., Ph.D., The University of Texas MD Anderson Cancer Center
Session: Sarcoma: Proffered Paper Sarcoma Session
Chair: Sebastian Bauer, MD., West German Cancer Center, University of Essen
Abstract #: 14730
Date and Time: Saturday, September 9, 2017, 11:00 AM – 12:30 PM (CEST)
About DCC-2618
DCC-2618 is currently in a first-in-human Phase 1 clinical trial. DCC-2618 is a pan-KIT and PDGFRα kinase switch control inhibitor in clinical development for the treatment of KIT and/or PDGFRα-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.
Contacts:
Media:
Gina Nugent, The Yates Network
gina@theyatesnetwork.com
617-460-3579
Investor Relations:
Laura Perry or Sam Martin, Argot Partners
Laura@argotpartners.com or Sam@argotpartners.com
212-600-1902
Company:
Christopher J. Morl, Chief Business Officer
Deciphera Pharmaceuticals, LLC
cmorl@deciphera.com
781-209-6418